In a patient with heart failure with reduced ejection fraction and an ejection fraction of 33% who is already decongested, should furosemide be continued?

Furosemide Should Be Continued at the Lowest Effective Dose to Maintain Euvolemia

In a decongested HFrEF patient with EF 33%, furosemide should be maintained at the minimum dose necessary to prevent recurrent congestion, while prioritizing optimization of guideline-directed medical therapy (GDMT) that improves mortality. Loop diuretics are essential for symptom management but do not reduce mortality—your primary focus should be ensuring this patient is on maximal tolerated doses of the four foundational HFrEF therapies.

The Role of Diuretics in Decongested HFrEF

Diuretics are recommended to improve symptoms and exercise capacity in patients with signs and/or symptoms of congestion 1. However, once decongestion is achieved, the approach changes fundamentally:

• Loop diuretics have no proven mortality benefit in HFrEF 2, 3
• They are symptomatic therapy only, indicated when congestion is present 1
• Diuretics may activate neurohormonal systems (RAAS, SNS) that worsen HF progression 4, 3
• High-dose or unnecessary diuretic use can cause hypovolemia, electrolyte disturbances, and hypotension that interferes with GDMT uptitration 5, 4

Practical Management Strategy

For your decongested patient:

1. Maintain furosemide at the lowest dose that prevents recurrent congestion (typically 20-40 mg daily) 4
2. Monitor daily weights at the same time each day 5
3. Assess for congestion signs at each visit: jugular venous distention, peripheral edema, orthopnea, dyspnea on exertion 5, 6
4. Adjust diuretic dose based on volume status, not by routine schedule 5

The Critical Priority: GDMT Optimization

Your primary therapeutic goal is ensuring this patient receives all four Class I mortality-reducing therapies 7, 8:

1. ACE inhibitor/ARB or ARNI (sacubitril/valsartan preferred if symptomatic on ACEi/ARB)
2. Beta-blocker (carvedilol, metoprolol succinate, or bisoprolol)
3. Mineralocorticoid receptor antagonist (spironolactone or eplerenone)
4. SGLT2 inhibitor (dapagliflozin or empagliflozin)

These medications reduce mortality by ≥20% each and decrease sudden cardiac death 7. With EF 33%, this patient absolutely requires all four classes unless contraindicated.

Common Pitfall: Diuretic-Induced Barriers to GDMT

Excessive diuretic use creates obstacles to optimal HFrEF therapy:

• Hypovolemia causes hypotension that prevents uptitration of ACEi/ARB/ARNI 5, 4
• Electrolyte depletion (hypokalemia, hyponatremia) complicates MRA use 4
• Worsening renal function from overdiuresis limits RAAS inhibitor dosing 5

The 2009 ACC/AHA guideline explicitly states: "transition should be made from intravenous to oral diuretic therapy with careful attention to oral diuretic dosing" 5, emphasizing that once decongested, the focus shifts to maintaining euvolemia with minimal diuretic exposure.

Monitoring and Adjustment Protocol

Establish a systematic approach:

• Daily weights: Instruct patient to call if weight increases >2-3 lbs in 1 day or >5 lbs in 1 week
• Flexible diuretic dosing: Teach patient to increase furosemide by 20-40 mg for 1-2 days if weight increases, then return to baseline dose 5
• Regular electrolyte monitoring: Check potassium, creatinine, BUN every 1-3 months on stable doses 5, 9
• Assess volume status clinically: Supine and standing blood pressure, JVP, edema, lung exam 5

When to Increase Diuretics

Increase furosemide dose if:

• Weight gain >2-3 lbs acutely
• New or worsening dyspnea, orthopnea, or edema
• Elevated jugular venous pressure
• Pulmonary crackles on examination

Do not routinely increase diuretics in stable, euvolemic patients 10. Research shows diuretic dose escalation is associated with increased HF hospitalizations and resource utilization, reflecting worsening disease rather than therapeutic benefit 10.

Evidence Synthesis

The 2016 ESC guidelines provide Class I, Level B recommendation: "Diuretics are recommended in order to improve symptoms and exercise capacity in patients with signs and/or symptoms of congestion" 1. This is symptom-directed therapy, not mortality-directed.

The 2022 AHA/ACC/HFSA guideline similarly emphasizes diuretics for symptomatic relief while prioritizing GDMT 8, 11. No guideline recommends routine high-dose diuretics in decongested patients.

The FDA label for furosemide indicates use "for the treatment of edema associated with congestive heart failure" 9, confirming its role is managing fluid overload, not chronic maintenance at high doses in euvolemic patients.

Key Caveats

• Never abruptly discontinue diuretics in HFrEF patients—even when decongested, most require some maintenance dose
• Diuretic resistance may develop; if congestion recurs despite dose escalation, consider adding thiazide (metolazone) or switching to torsemide 5, 4
• Renal function monitoring is essential: rising creatinine may reflect worsening HF (requiring more diuresis) or overdiuresis (requiring dose reduction) 5, 6
• Patients with improved EF (HFimpEF) who achieve EF >40% should continue GDMT indefinitely to prevent relapse, but may require less diuretic 8, 12

Bottom line: Maintain furosemide at the minimum effective dose while aggressively optimizing the four foundational GDMT medications that actually prolong life in this patient with EF 33%.